TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Validation of Nicom Device to Measure Stoke Volume Variation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing general anesthesia with an expected duration exceeding two hours~* gastrointestinal surgery, urological or gynecological surgery.~Exclusion Criteria:~* Difficulty of venous access.~* Contraindication for the use of oesophageal Doppler~* Contraindication for the use of Nicom~* Contraindication for the use of bispectral index~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low volume (Type: EXPERIMENTAL): The protocol will follow the following steps :~* basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* followed by low volume loading (250 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
- High volume (Type: EXPERIMENTAL): The protocol will follow the following steps :~* basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* followed by low volume loading (500 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prazosin for ETOH or Cocaine Craving

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70 years~* Current DSM-IV diagnosis of alcohol dependence or cocaine dependence with no use in last 30 days~* Capacity to provide informed consent~* Actively enrolled in chemical dependency treatment at VA Puget Sound English fluency~Exclusion Criteria:~* Evidence of significant abuse of opiates, PCP, sedatives or anxiolytics~* Suicidal ideation~* DSM IV diagnosis of bipolar mood disorder, schizophrenia or schizoaffective disorder~* Significant acute or chronic medical illness, including unstable angina, recent myocardial infarction, history of congestive heart failure, preexisting hypotension (systolic \< 110), or orthostatic hypotension (systolic drop \> 20mmHg after two minutes standing or any drop with dizziness), insulin-dependent diabetes mellitus; chronic renal or hepatic failure, pancreatitis, gout, M ni re's disease, benign positional vertigo, narcolepsy~* Concomitant use of alpha-1 antagonists History of prazosin-sensitivity Women who are pregnant, nursing infant(s), or of childbearing potential and not using a contraceptive method judged by the investigator to be effective~* Non-compliance with outpatient chemical dependency treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: OTHER): Placebo no active medication
- prazosin (Type: ACTIVE_COMPARATOR): Prazosin flexible dose titration up to 12 mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥ 18 years of age~* Diagnosis of at least probable idiopathic inflammatory myopathies (IIM) per European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria which includes confirmation of dermatomyositis (DM) rash/manifestation, disease activity defined by presence of DM rash / manifestation or an objective disease activity measure~* Disease severity defined by Physician global activity visual analog scale (VAS) with a minimum value of 2.0 cm on a 10 cm scale and MMT-8 ≤ 142 or CDASI total activity score ≥ 14.~* Corticosteroid daily dose less than that or equal to 20 mg prednisolone equivalent~Exclusion Criteria:~* Cancer-associated myositis~* Evidence of active malignant disease or malignancies diagnosed within the previous 5 years~* Physician Global Damage score ≥ 3, or clinically relevant improvement between Screening Visit and Baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Type: EXPERIMENTAL): human immunoglobulin G administered subcutaneously
- Placebo (Type: PLACEBO_COMPARATOR): human albumin solution administered subcutaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Intrauterine pregnancy \<12 weeks gestation (as confirmed by ultrasound)~2. Ability to undergo outpatient abortion without an anesthesiologist~3. Age ≥ 16 years old~4. Informed consent prior to participation in study~5. English or Spanish language capacity (or staff or professional translator available for all study procedures)~Exclusion Criteria:~1. Possible ectopic pregnancy~2. Known allergy to study medications or misoprostol~3. Current unstable psychiatric disorder~4. Current alcohol/drug/narcotic/benzodiazepine/barbituate dependence within the previous 2 months~5. Weight \< 50 kg

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Moderate sedation (Type: ACTIVE_COMPARATOR): None
- Oral medication (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary epithelial OC patients with measurable tumor lesions (determined by CT or MRI), who are intended to be treated with neo-adjuvant chemotherapy (carboplatin/paclitaxel), subsequent surgery and adjuvant chemotherapy~* Age ≥ 18 years~* Signed informed consent in accordance with institutional and regulatory guidelines~* Adequate access of the tumor for image-guided biopsy~* Adequate (according to the institutional standards) hematology, liver and kidney function to undergo chemotherapy with carboplatin and paclitaxel~* ECOG-performance status of 0 or 1 at screening~* Current BMI \> 18.5 and no weight loss of \>5% over the past month. Notably, weight loss due to drainage of ascites is not applicable.~Exclusion Criteria:~* History of a second malignancy except for curatively treated low-stage tumors with a histology that can be differentiated from the epithelial OC type~* History of an autoimmune disease, specifically HAV, HBV, HCV and HIV, or any other systemic intercurrent disease or condition that might affect the immunocompetence of the patient, or treatment with systemic highly immunosuppressive therapy (e.g. transplant recipients or patients who underwent a splenectomy)~* Use of systemic continuous corticosteroid therapy (e.g. prednisone i.v. or p.o. \>7.5 mg / day).~* Pregnancy or breast feeding~* Participation in a trial with another investigational drug within 30 days prior to the enrolment in this trial~* Any condition that in the opinion of the investigator could interfere with the conduct of the trial.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Patients will receive 8 W_ova1 vaccinations before and during neoadjuvant chemotherapy and adjuvant chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective CABG surgery.~* Signed, documented informed consent prior to admission to the study.~Exclusion Criteria:~* Unstable angina, requiring intervention or CABG \<24 hrs after screening.~* Decompensated congestive heart failure.~* Chronic, persistent, paroxysmal atrial fibrillation.~* Uncorrected significant valvular heart disease~* Known hypersensitivity to the study drug~* Left ventricular dysfunction (ejection fraction \<35%)~* Use of anti-arrhythmic drugs other than beta blockers~* Non-cardiac illness with a life expectancy of less than 1 year~* Bleeding diathesis or history of coagulopathy~* Significant renal and liver insufficiency~* Significant thyroid, pulmonary disease~* Uncontrolled diabetes mellitus~* Patients on anti-arrhythmic drugs~* Patients with pacemaker~* Patients unable to provide/sign informed consent.~* Patients currently taking marine based omega-three fish oil supplements.~* Disturbances in lipid metabolism, serum triglyceride value \>3 mmol/l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CABG and intralipid infusion (Type: PLACEBO_COMPARATOR): Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Intralipid Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
- CABG and omega-3 fatty acid infusion (Type: ACTIVE_COMPARATOR): Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Omegaven Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: At Home Early vs. Delayed Catheter Removal Following Failed Postoperative Voiding Trial: a Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking Age 18+ Undergoing pelvic reconstructive surgery with ERAS protocol Incomplete bladder emptying after same day VT in PACU (as defined by an ultrasound or straight catheter post void residual of greater than 50% the total instilled volume within 10 minutes following a void postoperatively) Able to complete a telephone appointment on either postoperative day 1 or 3~Exclusion Criteria:~* Active urinary tract infection, defined by CDC criteria Patients undergoing pelvic reconstructive surgery where ERAS protocol is not utilized (examples: isolated Labiaplasty, chemodenervation with onabotulinum toxin A, urethral bulking, mid-urethral sling, sacral neuromodulation) Contraindication to ERAS protocol and/or its medications Elevated pre-op PVR greater than 200mL (on urodynamic testing or uroflow or straight catheter sample, that remains elevated after prolapse is reduced) Limited manual dexterity (limiting self-removal of catheter) Intra-op cystotomy or urinary tract injury Planned long term catheterization (e.g., fistula repair, urethral diverticulum) Planned hospital admission or patients who are not discharged from hospital the same day of their surgery Pregnancy Dependent on catheterization to void preoperatively Patients who request clean intermittent catheterization (CIC) after immediate failed VT Neurological conditions that affect voiding function (examples: spinal cord lesions, multiple sclerosis, Parkinson's disease, past stroke history with residual neurologic deficits) Concomitant surgical procedure by another service Conversion to open surgery Patients discharged to nursing home or rehabilitation care facility

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- (Intervention group): self-removal of transurethral catheter on POD 1 (Type: EXPERIMENTAL): Subjects will self-remove transurethral catheter at home on postop day 1
- (Standard practice group): self-removal of transurethral catheter on POD 3 (Type: ACTIVE_COMPARATOR): Subjects will self-remove transurethral catheter at home on postop day 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Seropositive for HIV~* Age 18-70~* Report average of at least twice weekly heavy drinking~* Willing to reduce drinking to non-hazardous levels~* Verbal Intelligence Quotient (Verbal IQ) of 80 or higher~* Willing to provide signed informed consent~* Willing to nominate an individual to help locate the participant's whereabouts for follow-up~* If female: non-lactating and practicing a reliable method of birth control~Exclusion Criteria:~* Current clinically significant and/or uncontrolled physical disease (e.g., pancreatitis, diabetes)~* History of nephrolithiasis~* Severe psychiatric illness (i.e., psychosis or mania)~* Current diagnosis of drug abuse or dependence (other than nicotine abuse/dependence and cannabis abuse)~* Current diagnosis of alcohol dependence (AD) too severe for participation in a trial in which the goal is reduced drinking~* Gross cognitive impairment~* Glaucoma~* Serious/confounding neurological disease (e.g, stroke, seizure)~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Topiramate + Medical Management (Type: EXPERIMENTAL): Topiramate titrated up to 150 mg/day over 5 weeks then maintained for 6 weeks + Medical Management sessions for 15-25 minutes per study visit
- Placebo Pill + Medical Management (Type: PLACEBO_COMPARATOR): Sugar pill with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients from 2 to less than 7~* Primary diagnosis of ASD as per Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria~* Criteria met for ASD on Autism Diagnostic Observation Schedule-Generic (ADOS-2) and Autism Diagnosis Interview Revised (ADI-R)~* CGI (Clinical Global Impression) - Severity rating Score ≥ 4~* Childhood Autism Rating Scale second edition (CARS2-ST or HF) total raw score ≥ 34~* Social responsiveness Scale second edition (SRS-2) total score ≥ 66 T-Score~* Absence of diagnosis of Fragile X or Rett Syndrome~* Absence of any clinically significant abnormality likely to interfere with the conduct of the study according to the judgment of the investigator.~Exclusion Criteria:~* Patients not able to follow the study assessments defined by the protocol, with the exception of self-rating questionnaires which will be assessed by parent/legal representative/caregiver for those patients unable to complete them~* Patients having a high suicidal risk according to the investigator judgement~* Chronic renal dysfunction~* Chronic cardiac dysfunction~* Patient with unstable psychotherapy, behavioural, cognitive or cognitive-behavioural therapy~* Severe electrolyte imbalance that is likely to interfere with the study conduct or evaluation

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- BUMETANIDE (S95008) followed by Open-Label S95008 (Type: EXPERIMENTAL): Participants will receive S95008 for 6 months, 26 weeks, and then they will begin an open-label 6 month treatment period with S95008.
- PLACEBO followed by Open-Label S95008 (Type: PLACEBO_COMPARATOR): Participants will receive placebo for 6 months, 26 weeks, and then they will begin an open-label 6 month treatment period with S95008.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary or recurrent disease~* Histological confirmation of primary (or recurrent) and metastatic disease~* Systemic chemotherapy and/or biological is allowed before and/or after CRS+HIPC~* Radiotherapy is allowed before or after CRS+HIPC~* Patients must not have failed prior intraperitoneal platinum-therapy~* Age between 18 to 75 years~* Patient Karnofsky performance scale (KPS) \> 80 (normal activity with a bit of effort)~Exclusion Criteria:~* Age \< 18 or \> 75 years~* Pregnancy~* Any malignancy other than biliary, gastric, or pancreatic adenocarcinoma~* Any metastatic disease outside the abdominal compartment, such as pulmonary or bone metastases~* Peritoneal carcinomatosis index (PCI) \> 20 at the start of CRS~* Peritoneal residual tumour nodules larger than 2.5 mm after CRS (CCR-2)~* Clinical relevant ascites~* More than 3 liver metastases~* Solitary liver metastasis larger than 5 cm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CRS+HIPC (Type: EXPERIMENTAL): Patients with biliary, gastric, or pancreatic carcinoma and metastatic or recurrent disease confined to the abdominal compartment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluid Resuscitation in Septic Shock Patients With BMI Elevation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* BMI \> 30~* suspected infection, and either:~  * hypotension (a systolic blood pressure \< 90mmHg) or~ * blood lactate concentration \> 4mmol/L~Exclusion Criteria:~* Pregnant~* Primary diagnosis of acute cerebral vascular event~* Acute coronary syndrome~* Acute pulmonary edema~* Status asthmaticus~* Major cardiac arrhythmia~* Active gastrointestinal hemorrhage~* Seizures~* Drug overdose~* Burns or trauma~* Requirement for immediate surgery~* CD4\<50/mm3~* Do-not-resuscitate order status~* Transferred from another hospital

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30cc/kg ideal body weight (IBW) (Type: ACTIVE_COMPARATOR): 30cc/kg intravenous fluids based on the patients calculated ideal body weight will be administered when randomized to this arm~Using Devine's formula. (men: 50kg + 2.3kg \* (height(in) - 60); women: 45.5kg + 2.3kg \* (height(in) - 60)
- 30cc/kg adjusted body weight (AdjBW) (Type: ACTIVE_COMPARATOR): 30cc/kg intravenous fluids based on the patients calculated adjusted body weight will be administered when randomized to this arm~Calculated by the following formula: AdjBW = IBW + 0.4(ABW - IBW).
- 30cc/kg actual body weight (ABW) (Type: ACTIVE_COMPARATOR): 30cc/kg intravenous fluids based on the patients actual body weight will be administered when randomized to this arm~Patients will receive an initial fluid bolus of 30 cc/kg of actual body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues